Silas P. Trumbo, Cara B. Janusz, Barbara Jauregui, Mike McQuestion, Gabriela Felix, Cuauhtémoc Ruiz-Matus, Jon K. Andrus, and Ciro De Quadros, Vaccination legislation in Latin America and the Caribbean, Journal of Public Health Policy, Vol. 34, p. 82–99 (February 14, 2013), https://www.ncbi.nlm.nih.gov/pubmed/23407412 / https://link.springer.com/article/10.1057%2Fjphp.2012.66

Olivier Ethgen, Murielle Cornier, Emilie Chriv and Florence Baron-Papillon, The cost of vaccination throughout life: A western European overview, Human Vaccines & Immunotherapeutics, Volume 12, 2016, Issue 8, Pages 2029-2037, https://doi.org/10.1080/21645515.2016.1154649, https://www.tandfonline.com/doi/full/10.1080/21645515.2016.1154649, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994732/

UN

[edit]

European Community

[edit]

TITLE I: DEFINITIONS

Article 1

4. Immunological medicinal product:

Any medicinal product consisting of vaccines, toxins, serums or allergen products:

(a) vaccines, toxins and serums shall cover in particular:

(i) agents used to produce active immunity, such as cholera vaccine, BCG, polio vaccines, smallpox vaccine;

(ii) agents used to diagnose the state of immunity, including in particular tuberculin and tuberculin PPD, toxins for the Schick and Dick Tests, brucellin;

(iii) agents used to produce passive immunity, such as diphtheria antitoxin, anti-smallpox globulin, antilymphocytic globulin;

Article 114

1. Where it considers it necessary in the interests of public health, a Member State may require the holder of an authorization for marketing:

— live vaccines,

— immunological medicinal products used in the primary immunization of infants or of other groups at risk,

— immunological medicinal products used in public health immunization programmes,

— new immunological medicinal products or immunological medicinal products manufactured using new or altered kinds of technology or new for a particular manufacturer, during a transitional period normally specified in the marketing authorization,

to submit samples from each batch of the bulk and/or the medicinal product for examination

3.2.1.2. Manufacturing process of the active substance(s)

...

c) For biological medicinal products, the following additional requirements shall apply.

Whenever possible, vaccine production shall be based on a seed lot system and on established cell banks. For bacterial and viral vaccines, the characteristics of the infectious agent shall be demonstrated on the seed. In addition, for live vaccines, the stability of the attenuation characteristics shall be demonstrated on the seed; if this proof is not sufficient, the attenuation characteristics shall also be demonstrated at the production stage.

1.2. Vaccines For vaccines for human use and by derogation from the provisions of Module 3 on ‘Active substance(s)’, the following requirements when based on the use of a Vaccine Antigen Master File system shall apply. The marketing authorisation application dossier of a vaccine other than human influenza vaccine, shall be required to include a Vaccine Antigen Master File for every vaccine antigen that is an active substance of this vaccine.


Specific countries

[edit]

Australia

[edit]
Mandates
[edit]
Appointment of Enduring Guardian; depends on whether you have an Advanced Care Directive
Adverse events
[edit]
IP
[edit]

Austria

[edit]

Brazil

[edit]

Canada

[edit]

China

[edit]
2022

Colombia

[edit]

France

[edit]

Germany

[edit]

A form of emergency use of an investigational vaccine was employed in Germany in 2009, when a laboratory worker sustained a needlestick while handling Ebola virus. An investigational vaccine developed in Canada and based on vesicular stomatitis virus expressing an Ebola virus envelope glycoprotein was administered to the worker, who did not develop symptoms of disease (Enserink 2009).

Guatemala

[edit]

Hungary

[edit]

India

[edit]

Ireland

[edit]

Israel

[edit]

Italy

[edit]

Japan

[edit]

Netherlands

[edit]

New Zealand

[edit]

South Africa

[edit]

Turkey

[edit]

Ukraine

[edit]

UK

[edit]